459841-25-9

Upstream product

• 459841-24-8 3-methyl-4-[2-[N-(5-methyl-2-furylsulfonyl)amino]-4,5-5-dimethylphenoxymethyl]benzoic acid methyl ester 
• 513-38-2 Isobutyl iodide 
• 459841-23-7 4-(2-amino-4, 5-dimethylphenoxymethyl)-3-methylbenzoic acid methyl ester 
• 24078-25-9 4-hydroxymethyl-3-methylbenzoic acid methyl ester 
• 104447-92-9 4-bromomethyl-3-methylbenzoic acid methyl ester 
• 17100-58-2 4-bromo-2-methylbenzyl alcohol 
• 68837-59-2 4-bromo-2-methylbenzoic acid 
• 18087-10-0 4,5-dimethyl-2-nitrophenol 
• 95-65-8 3,4-Dimethylphenol 
• 459841-21-5 4-(2-nitro-4, 5-dimethylphenoxymethyl)-3-methylbenzoic acid methyl ester 

Relevant academic research and scientific papers

Optimization of sulfonamide derivatives as highly selective EP1 receptor antagonists

A series of 4-[(2-{isobutyl[(5-methyl-2-furyl)sulfonyl]amino}phenoxy)methyl]benzoic acids and 4-({2-[isobutyl(1,3-thiazol-2-ylsulfonyl)amino]phenoxy}methyl)benzoic acids were synthesized and evaluated for their EP receptor affinities and EP1 receptor anta

REMEDIES FOR DEPRESSION CONTAINING EP1 ANTAGONIST AS THE ACTIVE INGREDIENT

A pharmaceutical composition for the treatment and/or prevention of depression comprising a compound having an antagonistic activity for EP1 receptor which a prostaglandin E2 receptor subtype. EP1 antagonist is useful for

N-PHENYLARYLSULFONAMIDE COMPOUND, DRUG CONTAINING THE COMPOUND AS ACTIVE INGREDIENT, INTERMEDIATE FOR THE COMPOUND, AND PROCESSES FOR PRODUCING THE SAME

(R1 is COOH etc.; R2 is hydrogen, methyl, etc.; R3 and R4 are a combination of methyl and methyl, etc.; R5 is isopropyl etc.; Ar is thiazolyl, pyridyl, 5-methyl-2-furyl each optionally substituted wit